Kadimastem, founded in 2009 and based on patented technology from the Weizmann Institute of Science, is a clinical-stage biotechnology company specializing in cell therapy. The company focuses on developing off-the-shelf cell-based products aimed at treating diseases that currently have no cure. Kadimastem operates in the regenerative medicine market, targeting a global clientele that includes patients suffering from neurodegenerative diseases and other severe conditions. The business model revolves around leveraging its unique platform to produce and commercialize cell therapy solutions. Revenue is generated through the development and sale of these innovative treatments, as well as potential partnerships and licensing agreements.

Keywords: cell therapy, biotechnology, regenerative medicine, neurodegenerative diseases, clinical-stage, patented technology, off-the-shelf products, innovative treatments, global market, unmet medical needs.